|Articles|March 1, 2012
Summary and Closing of Discussion
Dr. Chernew summarizes key points of the discussion and asks members to add any additional information.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
2
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
3
60% of US Women Face Barriers to Postpartum, Mental Health Care
4
Counseling Vitiligo Patients on Time to Repigmentation
5